NasdaqCM - Delayed Quote USD

Eterna Therapeutics Inc. (ERNA)

1.9000 +0.0700 (+3.83%)
At close: May 31 at 4:00 PM EDT
1.8700 -0.03 (-1.58%)
After hours: May 31 at 7:55 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
115.0000
68.0000
--
--
--
Cost of Revenue
247.0000
236.0000
--
--
--
Gross Profit
-132.0000
-168.0000
--
--
--
Operating Expense
21,013.0000
20,506.0000
26,947.0000
27,429.0000
7,248.0000
Operating Income
-21,145.0000
-20,674.0000
-26,947.0000
-27,429.0000
-7,248.0000
Net Non Operating Interest Income Expense
-1,263.0000
-476.0000
-30.0000
-74.0000
-43.0000
Other Income Expense
-495.0000
-521.0000
2,443.0000
-94,978.0000
-19,240.0000
Pretax Income
-22,903.0000
-21,671.0000
-24,534.0000
-122,481.0000
-7,291.0000
Tax Provision
-4.0000
-3.0000
45.0000
64.0000
--
Net Income Common Stockholders
-22,915.0000
-21,684.0000
-24,595.0000
-122,561.0000
-7,291.0000
Diluted NI Available to Com Stockholders
-22,915.0000
-21,684.0000
-24,595.0000
-122,561.0000
-7,291.0000
Basic EPS
-4.25
-4.08
-8.06
-56.61
-3.51
Diluted EPS
-4.25
-4.08
-8.06
-56.61
-3.51
Basic Average Shares
5,384.7500
5,314.0000
3,051.0000
2,165.0000
2,075.7080
Diluted Average Shares
5,410.3310
5,314.0000
3,051.0000
2,165.0000
2,075.7080
Total Operating Income as Reported
-21,606.0000
-21,135.0000
-33,217.0000
-113,732.0000
-7,248.0000
Rent Expense Supplemental
5,184.0000
3,306.0000
640.0000
--
--
Total Expenses
21,260.0000
20,742.0000
26,947.0000
27,429.0000
7,248.0000
Net Income from Continuing & Discontinued Operation
-22,899.0000
-21,668.0000
-24,579.0000
-122,545.0000
-7,291.0000
Normalized Income
-22,687.0370
-21,481.0187
-27,410.3600
-53,211.7900
-7,291.0000
Interest Income
--
138.0000
--
--
--
Interest Expense
--
614.0000
30.0000
74.0000
43.0000
Net Interest Income
-1,263.0000
-476.0000
-30.0000
-74.0000
-43.0000
EBIT
-21,598.0000
-21,057.0000
-24,504.0000
-122,407.0000
-7,248.0000
EBITDA
-19,996.0000
-19,934.0000
-24,007.0000
-121,948.0000
-7,150.0000
Reconciled Cost of Revenue
247.0000
236.0000
--
--
--
Reconciled Depreciation
1,602.0000
1,123.0000
497.0000
459.0000
98.0000
Net Income from Continuing Operation Net Minority Interest
-22,899.0000
-21,668.0000
-24,579.0000
-122,545.0000
-7,291.0000
Total Unusual Items Excluding Goodwill
-212.0000
-187.0000
3,584.0000
-94,977.0000
--
Total Unusual Items
-212.0000
-187.0000
3,584.0000
-94,977.0000
--
Normalized EBITDA
-19,784.0000
-19,747.0000
-27,591.0000
-26,971.0000
-7,150.0000
Tax Rate for Calcs
0.0000
0.0000
0.0002
0.0003
--
Tax Effect of Unusual Items
-0.0370
-0.0187
752.6400
-25,643.7900
--
12/31/2020 - 8/29/1991

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CMRA Comera Life Sciences Holdings, Inc.
0.0227
0.00%
 
HSTO Histogen Inc.
0.1720
0.00%
 
MOR2.SG MorphoSys AG
16.50
-0.60%
 
64Z.BE Keymed Biosciences Inc
3.7800
+2.16%
 
688428.SS InnoCare Pharma Limited
7.50
+0.81%
 
MOR.BE MorphoSys AG
67.90
0.00%
 
4YL.F Nanoform Finland Oyj
1.9280
-2.72%
 
SLRX Salarius Pharmaceuticals, Inc.
0.4632
+0.37%
 
2162.HK Keymed Biosciences Inc.
32.200
+1.58%
 
2171.HK CARsgen Therapeutics Holdings Limited
6.870
-3.24%